Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) major shareholder Bros. Advisors Lp Baker purchased 2,783,605 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were bought at an average cost of $12.25 per share, for a total transaction of $34,099,161.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) traded up 1.49% during midday trading on Wednesday, hitting $13.63. The stock had a trading volume of 525,278 shares. The stock has a 50 day moving average of $10.77 and a 200 day moving average of $8.69. Aquinox Pharmaceuticals Inc. has a 12 month low of $6.01 and a 12 month high of $18.85. The stock’s market cap is $234.60 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.22. Analysts expect that Aquinox Pharmaceuticals Inc. will post ($2.11) EPS for the current fiscal year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/insider-buying-aquinox-pharmaceuticals-inc-aqxp-major-shareholder-purchases-2783605-shares-of-stock.html

Several equities research analysts have weighed in on AQXP shares. Jefferies Group increased their price target on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 21st. Finally, Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $19.86.

Several institutional investors have recently made changes to their positions in AQXP. Franklin Resources Inc. increased its position in Aquinox Pharmaceuticals by 7.6% in the first quarter. Franklin Resources Inc. now owns 1,245,945 shares of the company’s stock worth $10,989,000 after buying an additional 87,600 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Aquinox Pharmaceuticals by 5,277.2% in the first quarter. Goldman Sachs Group Inc. now owns 970,317 shares of the company’s stock worth $8,558,000 after buying an additional 952,272 shares in the last quarter. BlackRock Inc. increased its position in Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock worth $446,000 after buying an additional 9,900 shares in the last quarter. Royce & Associates LP increased its position in Aquinox Pharmaceuticals by 416.4% in the first quarter. Royce & Associates LP now owns 96,167 shares of the company’s stock worth $848,000 after buying an additional 77,545 shares in the last quarter. Finally, BlackRock Group LTD increased its position in Aquinox Pharmaceuticals by 23.4% in the first quarter. BlackRock Group LTD now owns 200,100 shares of the company’s stock worth $1,765,000 after buying an additional 37,900 shares in the last quarter. 89.41% of the stock is currently owned by institutional investors and hedge funds.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

5 Day Chart for NASDAQ:AQXP

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.